Ipsen (FR:IPN)
:IPN
Want to see FR:IPN full AI Analyst Report?
IPN Stock Chart & Stats
€161.80
€0.40(0.34%)
At close: 4:00 PM EST
€161.80
€0.40(0.34%)
Day’s Range― - ―
52-Week Range€100.00 - €173.50
Previous CloseN/A
Volume2.80K
Average Volume (3M)64.26K
Market Cap
€12.81B
Enterprise Value€12.56B
Total Cash (Recent Filing)€1.53B
Total Debt (Recent Filing)€1.05B
Price to Earnings (P/E)22.4
Beta0.52
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.17%
Share Statistics
EPS (TTM)5.36
Shares Outstanding83,814,530
10 Day Avg. Volume52,964
30 Day Avg. Volume64,259
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€143.80Price Target Upside-11.12% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)12.85
Revenue Forecast (FY)€4.22B
Bulls Say, Bears Say
Bulls Say
Specialty-focused PortfolioIpsen's focus on oncology, rare diseases and neuroscience creates durable competitive barriers and pricing power. Specialization supports higher margins, targeted R&D, and resilient demand across diversified therapeutic areas and international channels over the medium term.
Multi-year Revenue Growth & ProfitabilityConsistent revenue expansion with sustained EBITDA margins near 30% shows structural operating strength. That profitability supports reinvestment in R&D and commercial rollout, enabling continued product development and scalable commercialization over the next several months.
Improved Cash Generation In 2025A ~€1.03B FCF and FCF/net income ~0.91 in 2025 indicates higher earnings quality and internal funding capacity. Strong cash conversion provides durable flexibility to fund R&D, milestone payments, and debt servicing without heavy reliance on external financing.
Bears Say
Margin Compression Since 2021–2023A material drop in net margin from prior years suggests structural cost, pricing or mix pressures. Prolonged margin erosion can reduce free cash flow and ROE, limiting capacity for R&D, commercial investment and shareholder returns across the medium term.
Sharp Step-up In Total Debt In 2025An abrupt increase in total debt reduces financial flexibility even if leverage remains moderate (debt/equity ~0.24). Higher indebtedness raises interest and refinancing risk and can constrain capital allocation if cash flows slip in the coming months.
Historically Volatile Free Cash Flow ConversionInconsistent FCF generation, with a notable weak 2024, signals execution and working-capital variability. That volatility complicates planning for R&D, milestone payments and M&A, increasing liquidity and operational risk over the 2–6 month horizon.
IPN FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest stock price was €100.00 and its highest was €173.50 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €12.81B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Jul 30, 2026 which is in 70 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Feb 12, 2026. The company reported €6.02 earnings per share for the quarter, beating the consensus estimate of €5.527 by €0.493.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Overvalued.
Does Ipsen pay dividends?
Ipsen pays a Annually dividend of €1.4 which represents an annual dividend yield of 1.17%. See more information on Ipsen dividends here
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €6.02 in its last earnings report, beating expectations of €5.527. Following the earnings report the stock price went up 6.34%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in FR:IPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
IPN Stock 12 Month Forecast
Average Price Target
€143.80
▼(-11.12% Downside)
Technical Analysis
Options Prices
Currently, No data available
---